Expertise in
3
conditions

Lars Stechemesser

Salzburg, AT 
Expertise in
3
conditions
Salzburg, AT 

Overview

Lars Stechemesser practices practicing medicine in Salzburg, Austria.

Mr. Stechemesser is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Maturity Onset Diabetes of the Young, Diabetic Nephropathy, Type 2 Diabetes (T2D), and Type 1 Diabetes (T1D).

He is actively involved in clinical research, co-authoring 38 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Salzburg, Austria
Other Locations
Vienna, 1090, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: July 08, 2026
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: January 19, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
Enrollment Status: Completed
Publish Date: January 22, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

38 Total Publications

Antihyperglycemic treatment of type 2 diabetes mellitus (Update 2026)
Antihyperglycemic treatment of type 2 diabetes mellitus (Update 2026)
Journal: Wiener klinische Wochenschrift
Published: January 02, 2026

Frequently Asked Questions about Lars Stechemesser

Is Lars Stechemesser a top-rated expert for Maturity Onset Diabetes of the Young?

MediFind is an objective health platform that identifies experts based on real-world data. Lars Stechemesser is classified as an Advanced expert for Maturity Onset Diabetes of the Young, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Lars Stechemesser participate in research or clinical trials?

Yes. Lars Stechemesser has published 38 articles and abstracts on conditions like Maturity Onset Diabetes of the Young. You can view a list of Lars Stechemesser's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Stechemesser's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile